We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Smartphone-Based Optical Imaging Offers Onsite Diagnostics

By LabMedica International staff writers
Posted on 08 Feb 2017
A novel smartphone-based optical imaging and molecular assay system permits on-site diagnostics and facilitates transfer of molecular diagnostic data from the point-of-care (POC) to the point-of-expertise, providing a cost-effective means for molecular diagnostics even in resource-limited settings.

The device, which can image and analyze specific DNA sequences and genetic mutations in tumor cells and tissue samples without prior DNA extraction, was developed through the collaborative efforts of a group of investigators at the University of California, Los Angeles, Stockholm University, and Uppsala University.

The investigators used a three-dimensional printer to produce a lightweight optical attachment to be used with a standard smartphone camera. More...
The device is able to capture multi-color fluorescence and bright-field images of the same quality as those obtained by traditional light microscopy.

The device analyzes a tissue or cell sample in a dedicated container by recording multi-mode images of the sample during processing and feeding the data to an algorithm. The algorithm automatically analyzes the images to read the sequenced bases of the extracted tumor DNA and identifies genetic mutations directly inside the tumor tissue.

“It is very important to have these molecular testing approaches at a doctor’s office or where care is being given,” said senior author Dr. Mats Nilsson, professor of biochemistry and biophysics at Stockholm and Uppsala Universities. “Oftentimes, advanced lab-based testing is performed at major hospitals, which is limiting, as not everyone has access to a hospital that can perform these tests.”

The device was described in detail in the January 17, 2017, online edition of the journal Nature Communications.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Automated Immunoassay Analyzer
SuperFlex™
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.